Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Eli Lilly

The battle for the multibillion-dollar obesity market just got fiercer. Amgen Inc's AMGN new drug candidate, MariTide, reported promising results, helping patients shed around 20% of their body weight.

Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance

MPLX

With markets surging, finding high-yield bargains can feel impossible. Yet, opportunities still exist for disciplined, value-focused investors. My strategy targets strong, dividend-paying businesses trading below their true worth. These picks combine yield, growth, and resilience. By focusing on fundamentals and long-term potential, I've identified two standout stocks. They're not just high-yield, they're future-proof investments.

Bargain Hunting In A Pricey Market: 2 High-Yield Dividend Picks That Have Me Hooked

THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m.

AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE

The biotech industry can be volatile even for relatively large companies. Amgen (AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact.

This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?

The market didn't appreciate Amgen's (AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more than 12% at one point on Nov. 26 from the previous day's close, though they recovered to close just 4.7% down for the day.

Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?

THOUSAND OAKS, Calif. , Nov. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m.

AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE

Even though Amgen is weak below the 200-day line, there's still a way to profit. The post Wide Trading Range For Amgen Stock Makes This Option Shine appeared first on Investor's Business Daily.

Wide Trading Range For Amgen Stock Makes This Option Shine

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Shares of Amgen (AMGN 0.02%) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market rose nearly 3% in the same period. The clear culprit for the drop is, quite regrettably for shareholders, an unintentional disclosure of clinical trial information that the market found to be rather unappetizing.

Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?

Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.

AMGN Stock Down Despite Strong Data From Obesity Drug Study

Amgen's MariTide shows up to 20% weight loss in Phase II, leaving room for improvement beyond 52 weeks, as weight loss did not plateau. GI side effects are a concern, but Amgen plans to address them through dose escalation strategies. The convenience of monthly or less frequent dosing leads to a differentiated profile. MariTide's potential as the first monthly treatment for type 2 diabetes enhances its competitive edge.

Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You

Shares of Amgen (AMGN -4.76%) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.

Why Amgen's Weight Loss Result Is a Win for Eli Lilly

Investors see Scott Bessent as a safe shepherd of the economy as the president-elect burnishes his "Tariff Man" reputation.

Stock Market Today: The S&P 500 Reclaims the 6K Level

Shares of Amgen fell after the company reported underwhelming phase 2 data with weight loss up to 20% in obese patients after 52 weeks of treatment. The results underperformed Street expectations. I believe the data the company reported today is not as bad as the market reaction suggests.

Amgen: MariTide Underwhelms, But There Are Ways To Win

Amgen (AMGN) shares tanked Tuesday after results from a test of the biotech's experimental weight-loss drug came in below expectations.

Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations

Abbott Labs

Boston Scientific

Salesforce

Gilead Sciences

Goldman Sachs

Intuit

Medtronic

Stryker

Tesla

Large-cap stocks are key additions to any well-rounded portfolio, but how do you find the best ones? We take a closer look here.

The Best Large-Cap Stocks to Buy

Kohl's

The S&P 500 and Nasdaq Composite rose on Tuesday, while Dow Jones slipped as investors assessed the threat of new tariffs from President-elect Donald Trump.  The S&P 500 index rose 0.2%, while the Nasdaq Composite climbed more than 0.5%.

S&P, Nasdaq climb while Dow dips amid Trump tariff concerns; Amgen, Kohl's shares tumble

Amgen Inc (NASDAQ:AMGN, ETR:AMG) shares tumbled 11.6% to a year's low after results of a trial for its potential weight-loss drug showed it helped overweight or obese people lose up 20% of weight over a year.  The Phase II study showed MariTide enabled up to around 20% average loss of weight without a plateau, with the company saying it is the first obesity treatment at this clinical stage with monthly or less frequent dosing to demonstrate such effective weight-loss capabilities safely.

Amgen tumbles to year's low despite weightloss trial success

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound. The post Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test appeared first on Investor's Business Daily.

Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test

Amgen Inc (NASDAQ: AMGN) says patients on its weight-loss injection in a mid-stage trial weighed up to 20% less on average after a year.

Amgen's weight-loss injection cuts up to 20% in a year

On Tuesday, Amgen Inc AMGN stock fell during the premarket session after the company released long-anticipated data from the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) in obese patients.

Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau

The pharmaceutical company's MariTide treatment performed well in a phase 2 study.

Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.

Amgen's MariTide achieves up to 20% weight loss in mid-stage trial, but analysts were expecting up to 25%.

Amgen's stock slides 7.8% after weight-loss drug data lags analyst expectations

Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, with no plateau, in a critical mid-stage trial. But the results appear to be at the low end of Wall Street's expectations.

Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau

Amgen's experimental drug MariTide led to average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.

News for Amgen Stock (AMGN)